Drugs / CT0180
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04756648 | Mar 2021 → Mar 2023 overdue | hepatocellular carcinoma | Zhejiang University | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT0180 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04756648 ↗ |
| Modality | Cell therapy | “CT0180 Cells” NCT04756648 ↗ |
| Target | GPC3 | “CT0180 humanized anti GPC3 autogenous T Cell injection” NCT04756648 ↗ |